LUNG - NASDAQ
Pulmonx Corporation
$1.60
+1.9%Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotPulmonx Corporation Management Team
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Compensation
$632,293
Mr. Steven S. Williamson
Chief Executive Officer, President & Director
Compensation
$945,343
Mr. Mehul Joshi
Chief Financial Officer
Compensation
$733,744
Ms. Lisa Paul
Chief People Officer
Mr. Sri Radhakrishnan
Chief Technical Officer
Mr. David A. Lehman J.D.
General Counsel & Secretary
Compensation
$628,726
Mr. Jérôme Erath
Senior Vice President & GM of Europe Middle-East & Africa
Ms. Lauren Cristina
Vice President of Finance & Administration (U.S.)
Ms. Marcee M. Maroney
Vice President of Marketing
Ms. Sarah Huber
Vice President of Sales (U.S.)
Pulmonx Corporation Insider Positioning
During the last 12 months, insiders have purchased $71K and sold $99K worth of LUNG shares, resulting in $28K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
24.1K
47.49K
-47K
-$47K
6-9 Months
0
0.00
2.5K
3.96K
-4K
-$4K
9-12 Months
23.3K
71.36K
21.9K
47.50K
+24K
+$24K
Top Buyers
Florin Daniel P
Director
$71K
Top Sellers
Florin Daniel P
Director
$46K
Ferrari Richard
Director
$25K
Williamson Steven S.
Director, Officer: President And Ceo
$7K
Joshi Mehul
Officer: Chief Financial Officer & Pao
$6K
Lehman David Aaron
Officer: General Counsel
$5K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $28K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
LUNG - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2025 | May 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 16, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 04, 2023 | May 17, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 15, 2022 | May 26, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 09, 2021 | May 20, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.